A Phase 1 interventional study of PF-03084014 in Neoplasms by Histologic Type, sponsored by Pfizer. Completed at 10 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2019-11-12.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Leukemia by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Leukemia · Pfizer.
Among the 19 studies in Leukemia by Pfizer, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2009, is one of 4 in phase 1, and was the 14th registered.
2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.
Browse Leukemia studies →1 of the 19 studies in Leukemia by Pfizer is open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in Austria, Belgium, Czechia and 12 more countries
Ages 1–17
By country, each count listing its studies:
Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 1 · Phase 4 4
First in 1997; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 40 across 1,770 interventional studies indexed under Leukemia.
Median enrollment 72 across the 17 interventional studies, 651 across the 2 observational. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Leukemia by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia
2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.
This study's enrollment of 72 is above the median of 40 across 1,770 interventional studies indexed under Leukemia.
Browse Leukemia studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Leukemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms by Histologic Type. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-03084014
10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
Also known as: gamma secretase inhibitor
Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT)
Any DLT event attributable to PF-03084014 during Cycle 1: non-hematologic toxicities \>= Grade 3 despite optimal care; treatment delay \>=7 days or unable to deliver at least 80% of planned dose due to treatment-related toxicities; Grade 4 neutropenia \>7 days; febrile neutropenia; neutropenic infection; Grade \>=3 thrombocytopenia with bleeding
Time frame: Baseline to the end of Cycle 1 (Week 4)
Number of T-ALL/LBL Participants With First-Cycle DLT
Any DLT attributable to PF-03084014 at 1st Cycle: non-hematologic toxicities \>= Grade 3 despite optimal care; treatment delay \>=7 days; unable to deliver at least 80% of planned dose; absolute neutrophil count (ANC) \<1000/microliter (uL), or platelet count \<30,000/uL, or hemoglobin \<8 gram/deciliter (g/dL) in a bone marrow with \<5% blasts and no evidence of leukemia or abnormal dysplasia for \>42 days
Time frame: Baseline to the end of Cycle 1 (Week 4)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causality)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of casual relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), and resulted in congenital anomaly/birth defect.
Time frame: Baseline up to end of study (maximum of 84 months)
Number of Participants With TEAEs (Treatment-Related)
An AE was any untoward medical occurrence in a participant who received study drug. Treatment-related events were those assessed by the investigator as related to study medication. An SAE was any untoward medical occurrence at any dose that: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), and resulted in congenital anomaly/birth defect.
Time frame: Baseline up to end of study (maximum of 84 months)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causality) by Severity (by Maximum Common Terminology Criteria for Adverse Events [CTCAE] Grade)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. CTCAE version 3.0 was used for AE grading: Grade 1 mild AE; Grade 2 moderate AE; Grade 3 severe AE; Grade 4 life-threatening or disabling AE; Grade 5 death related to AE.
Time frame: Baseline up to end of study (maximum of 84 months)
Number of Participants With TEAEs (Treatment-Related) by Severity (by Maximum CTCAE Grade)
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-related events were those assessed by the investigator as related to study medication. CTCAE version 3.0 was used for AE grading: Grade 1 mild AE; Grade 2 moderate AE; Grade 3 severe AE; Grade 4 life-threatening or disabling AE; Grade 5 death related to AE.
Time frame: Baseline up to end of study (maximum of 84 months)
Number of Participants With Potentially Clinical Significant Categorical Changes From Baseline in Electrocardiogram (ECG) Findings in QTc Interval
Criteria for potentially important changes in ECG were defined as: maximum (max.) post-dose (post-baseline) time from electrocardiogram Q wave to the corresponding to electrical systole (QT interval) corrected for Fridericia's factor (QTcF), or QT interval corrected for Bazett's factor (QTcB): \<450, 450 -\<480, 480-\<500, and \>=500 msec. Maximum increase (inc.) from baseline in QTcF or QTcB: change (chg) \<30, 30\>=chg\<60, and chg \>=60 msec.
Time frame: Baseline up to end of study (maximum of 84 months)
Number of Participants With Laboratory Tests Abnormalities Meeting the Criteria of Potential Clinical Concern (Hematology and Chemistries, All Cycles)
Parameters analyzed included: white blood cell (WBC) count plus differential, absolute (abs) neutrophil count, platelets, hemoglobin, sodium, potassium, bicarbonate, chloride, blood urea nitrogen, creatinine, glucose, uric acid, calcium, phosphate, magnesium, total protein, albumin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), partial prothrombin time/international normalized ratio (PTT/INR). Urinalysis: pH, specific gravity, protein, glucose, ketones, blood, leukocyte esterase, and nitrites. Pregnancy test: Serum or urine pregnancy test for women of childbearing potential. There were no changes in urine protein among the solid tumor and T-ALL/LBL participants that were clinically significant. Clinical significance was judged by the investigator.
Time frame: Baseline up to end of study (maximum of 84 months)
Maximum Observed Serum Concentration (Cmax) After a Single Dose on Cycle 1 Day 1
Cmax was the maximum observed serum concentration.
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)
Dose-normalized Cmax [Cmax (dn)] After a Single Dose on Cycle 1 Day 1
Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)
Area Under the Time-Concentration Curve From Time 0 to the Dosing Interval (AUCtau) After a Single Dose on Cycle 1 Day 1
AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). CV is the coefficient of variation.
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)
Dose-normalized AUCtau [AUCtau (dn) ] After a Single Dose on Cycle 1 Day 1
AUCtau (dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. NE is not estimable.
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)
Time to Reach Cmax (Tmax) After a Single Dose on Cycle 1 Day 1
Tmax was the time to reach maximum serum concentration (Cmax).
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)
Cmax After Multiple Dose on Cycle 1 Day 21
Cmax was the maximum observed serum concentration. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant. CV is the coefficient of variation.
Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Time to Reach Cmax (Tmax) After Multiple Dose on Cycle 1 Day 21
Tmax was the time to reach maximum serum concentration (Cmax). Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
AUCtau After Multiple Dose on Cycle 1 Day 21
AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Apparent Volume of Distribution (Vz/F) on Cycle 1 Day 21
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired concentration of a drug. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Serum Decay Half-Life (t1/2) After Multiple Dose on Cycle 1 Day 21
Serum decay half-life (t1/2) is the time measured for the serum concentration to decrease by one half. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Apparent Oral Clearance (CL/F) on Cycle 1 Day 21
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Minimum Observed Serum Concentration (Cmin) After Multiple Dose on Cycle 1 Day 21
Cmin was the minimum serum concentration. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Average Serum Concentration (Cavg) at Steady State on Cycle 1 Day 21
Cavg was the average serum concentration at steady state. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Accumulation Ratio (Rac) on Cycle 1 Day 21
Accumulation was calculated as AUCtau at steady state (Cycle 1 Day 21) divided by AUCtau after a single dose on Cycle 1 Day 1. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose), Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Dose-normalized AUCtau [AUCtau (dn)] After Multiple Dose on Cycle 1 Day 21
AUCtau (dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Dose-normalized Cmax [Cmax (dn)] After Multiple Dose on Cycle 1 Day 21
Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
AUCtau in the Fasted State for Solid Tumor Participants
AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval).
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
AUCtau in the Fed State for Solid Tumor Participants
AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval).
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Cmax in the Fasted State for Solid Tumor Participants
Cmax was the maximum observed serum concentration.
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Cmax in the Fed State for Solid Tumor Participants
Cmax was the maximum observed serum concentration.
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Dose-normalized AUCtau [AUCtau(dn)] in the Fasted State for Solid Tumor Participants
AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose.
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Dose-normalized AUCtau [AUCtau(dn)] in the Fed State for Solid Tumor Participants
AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose.
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Dose-normalized Cmax [Cmax(dn)] in the Fasted State for Solid Tumor Participants
Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Dose-Normalized Cmax [Cmax(dn)] in the Fed State for Solid Tumor Participants
Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.
Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose).
AUCtau on Cycle 2 Day 1
AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). Data for this outcome measure was planned to be analyzed for two arms only.
Time frame: Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Dose-normalized AUCtau [AUCtau (dn)] on Cycle 2 Day 1
AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. Data for this outcome measure was planned to be analyzed for two arms only.
Time frame: Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Cmax on Cycle 2 Day 1
Cmax was the maximum observed serum concentration. Data for this outcome measure was planned to be analyzed for two arms only.
Time frame: Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Dose-normalized Cmax [Cmax (dn)] on Cycle 2 Day 1
Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose. Data for this outcome measure was planned to be analyzed for two arms only.
Time frame: Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Tmax on Cycle 2 Day 1
Tmax was the time to reach maximum serum concentration (Cmax). Data for this outcome measure was planned to be analyzed for two arms only.
Time frame: Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Percentage of Solid Tumor Participants With Objective Response (OR)
Objective response (OR) was defined as confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as \>=30% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study \>=4 weeks after initial documentation of response.
Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (plus [+] or minus [-] 5 days) of every odd cycle or as clinically indicated, up to Cycle 9; afterwards assessed on Day 1 (+ or -5 days) every 4 cycles
Time to Tumor Progression (TTP) for Solid Tumor Participants
Time from Cycle 1 Day 1 to first documentation of disease progression. Progression was defined as per RECIST version 1.0, as a 20% increase in the sum of the longest diameter of target lesions, or target lesions over nadir, uneuivocal progression of non-target disease, or the appearance of new lesions. TTP (months) was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.
Time frame: Baseline until first documented objective progression (up to maximum of 84 months)
Duration of Response (DR) for Solid Tumor Participants
Time from the first documentation of OR to objective disease progression or death due to any cause. DR was only calculated for participants with an OR. DR (months) was calculated as (date of first documentation of objective progression or death minus date of first documentation of PR or CR plus 1) divided by 30.
Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or -5 days) of every odd cycle or as clinically indicated, up to Cycle 9. Afterwards, assessed on Day 1 (+ or -5 days) every 4 cycles (up to maximum of 84 months)
Progression-Free Survival (PFS) for Solid Tumor Participants
PFS was defined as the time from Cycle 1 Day 1 to date of first documentation of progression or death due to any cause. Progression was defined as per RECIST version 1.0, as a 20% increase in the sum of the longest diameter of target lesions, or target lesions over nadir, unequivocal progression of non-target disease, or the appearance of new lesions. PFS (months) was calculated as (the first event date minus the date of first dose of study medication plus 1) divided by 30.
Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9; afterwards assessed on Day 1 (+ or -5 days) every 4 cycles (up to maximum of 84 months)
Percentage of T-ALL/LBL Participants With OR
OR was adapted from International Working Group Response Criteria for Acute Myeloid Leukemia (AML). The response categories of interest were CR, complete response with incomplete hematopoietic recovery (CRi), and PR. CR: ANC \>1500/microliter (uL), no circulating blasts. Platelets \>100,000/uL, \<5% marrow blast cells, no extramedullary disease, bone marrow cellularity \>20% with tri-lineage hematopoiesis and \<5% marrow blast cells, none of which were neoplastic; CRi: same as CR but ANC may be \>1500/uL or platelet count \>100,000/uL, no requirement on bone marrow cellularity; PR: same as CR but bone marrow with \>= 50% reduction of leukemia blast cells and an absolute blast count between 5% and 25%.
Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9 (up to maximum of 84 months)
Relapse Free Survival (RFS) for T-ALL/LBL Participants
The RFS of CR was defined as the time from the date of first attaining CR to the date of relapse or death from any cause, whichever occurred first. Similarly, the RFS of CR + CRi (or RFS of CR + CRi + PR) was defined as the time from the date of first attaining CR + CRi (or CR + CRi + PR) to the date of relapse or death from any cause, whichever occurred first.
Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9 (up to maximum of 84 months)
Peripheral Blast Count Reduction (PBR) for T-ALL/LBL Participants
PBR was the maximum percentage of peripheral blast count reduction for each participant who received at least one dose of study medication. PBR was derived by the Sponsor from percentage of peripheral blood Blast Count reported by sites.
Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9 (up to maximum of 84 months)
Changes in Expression Levels of Notch 1 Target Genes in Tumor Biopsies for Solid Tumor Participants: Hairy and Enhancer of Split-4 (Hes4) Gene Expression Levels on Cycle 1 Day 21 Relative to That at Baseline
Gene expression analysis in tumor biopsies was done using cDNA prepared from RNA extracted from tumor biopsies. Gene expression was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Only Hes4 gene showed consistent down modulation across dosing cohorts (150 mg and 220 mg BID) and therefore results were reported for Hes4 only. Data for this outcome measure was planned to be analyzed for two arms only.
Time frame: Baseline, Cycle 1 Day 21 (-5 days)
Changes From Baseline in Expression Levels of Notch 1 Target Genes in Peripheral Blood for T-ALL/LBL Participants: Hes4 Gene Expression Levels on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 21 Relative to That at Baseline
Ribonucleic acid (RNA) was extracted from peripheral blood and used as a template to synthesize complementary deoxyribonucleic acid (cDNA). Gene expression in cDNA was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Results were reported Only for Hes4 as this was the only gene to show consistent down modulation across dosing cohorts (150 mg and 220 mg).
Time frame: Baseline (morning), Cycle 1 Days 8, 15 and 21 (morning, matched with the first PK sample of the particular day), Cycle 1 Day 21 (24, 48, and 120 hr post-dose) and at end of treatment (EOT)
Changes in Expression Levels of Notch 1 Target Genes in Peripheral Blood for Solid Tumor Participants: Hes4 Gene Expression Level on Cycle 1 Day 8 and Cycle 1 Day 21 Relative to That at Baseline
Ribonucleic acid (RNA) was extracted from peripheral blood and used as a template to synthesize complementary deoxyribonucleic acid (cDNA). Gene expression in cDNA was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Results were reported Only for Hes4 as this was the only gene to show consistent down modulation across dosing cohorts (150 mg and 220 mg).
Time frame: Baseline (morning), Cycle 1 Days 8 and 21 (pre-dose)
Changes From Baseline in Notch Intracellular Domain (NICD) Levels in Peripheral Blood for T-ALL/LBL Participants
Notch intracellular domain (NICD) levels was measured in peripheral blood mononuclear cell (PBMC) pellets using a validated enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, Cycle 1 Days 8 and 15 (pre-dose AM), Cycle 1 Day 21 (pre-dose AM and 24, 48 and 120 hr post-dose) and end of treatment (EOT).
Changes From Baseline in Notch Intracellular Domain (NICD) Levels in Bone Marrow for T-ALL/LBL Participants
Notch intracellular domain (NICD) was to be measured in bone marrow monoculear cell (BMMC) cell pellets using a validated ELISA.
Time frame: Baseline, Cycle 1 Day 1 and Cycle 2 Day 1
This study originally planned to give PF-03084014 in combination with dexamethasone in participants with solid tumors and with T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma, including a drug-drug-interaction test of PF-03084014 and dexamethasone in solid tumor participants. But these parts were removed per protocol amendments.
| Milestone | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 8 | 4 | 23 | 16 | 3 | 8 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 4 | 8 | 4 | 23 | 16 | 3 | 8 |
| Withdrew: Death | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Participant refused to follow-up | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Withdrew: Other | 3 | 2 | 4 | 7 | 4 | 18 | 15 | 3 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Objection progression or relapse | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
Any DLT event attributable to PF-03084014 during Cycle 1: non-hematologic toxicities \>= Grade 3 despite optimal care; treatment delay \>=7 days or unable to deliver at least 80% of planned dose due to treatment-related toxicities; Grade 4 neutropenia \>7 days; febrile neutropenia; neutropenic infection; Grade \>=3 thrombocytopenia with bleeding
| participants | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants |
|---|---|---|---|---|---|---|---|---|
| Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT) | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 2 |
Any DLT attributable to PF-03084014 at 1st Cycle: non-hematologic toxicities \>= Grade 3 despite optimal care; treatment delay \>=7 days; unable to deliver at least 80% of planned dose; absolute neutrophil count (ANC) \<1000/microliter (uL), or platelet count \<30,000/uL, or hemoglobin \<8 gram/deciliter (g/dL) in a bone marrow with \<5% blasts and no evidence of leukemia or abnormal dysplasia for \>42 days
| participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|
| Number of T-ALL/LBL Participants With First-Cycle DLT | 1 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of casual relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), and resulted in congenital anomaly/birth defect.
| participants | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|---|
| No. of Participants With AEs | 3 | 3 | 4 | 7 | 4 | 23 | 16 | 3 | 8 |
| No. of Participants With SAEs | 1 | 1 | 2 | 4 | 2 | 8 | 7 | 2 | 4 |
| No. of Participants Discontinued PF-03084014 | 0 | 1 | 0 | 2 | 1 | 1 | 4 | 2 | 3 |
| No. of Participants Temp. Discontinued Treatment | 1 | 1 | 2 | 1 | 1 | 9 | 5 | 1 | 0 |
| No. of Participants With Dose Reduction Due to AEs | 0 | 0 | 0 | 0 | 1 | 4 | 3 | 1 | 1 |
An AE was any untoward medical occurrence in a participant who received study drug. Treatment-related events were those assessed by the investigator as related to study medication. An SAE was any untoward medical occurrence at any dose that: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), and resulted in congenital anomaly/birth defect.
| participants | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|---|
| No. of Participants With AEs | 2 | 1 | 2 | 6 | 4 | 20 | 16 | 3 | 5 |
| No. of Participants With SAEs | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 |
| No. of Participants Discontinued PF-03084014 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 |
| No. of Participants Temp. Discontinued Treatment | 0 | 0 | 0 | 0 | 1 | 7 | 4 | 1 | 0 |
| No.of Participants With Dose Reduction Due to AEs | 0 | 0 | 0 | 0 | 1 | 4 | 3 | 1 | 1 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. CTCAE version 3.0 was used for AE grading: Grade 1 mild AE; Grade 2 moderate AE; Grade 3 severe AE; Grade 4 life-threatening or disabling AE; Grade 5 death related to AE.
| participants | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|---|
| Any AEs, Grade 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 |
| Any AEs, Grade 2 | 2 | 1 | 0 | 1 | 2 | 8 | 3 | 0 | 1 |
| Any AEs, Grade 3 | 1 | 1 | 2 | 2 | 2 | 12 | 9 | 2 | 4 |
| Any AEs, Grade 4 | 0 | 0 | 1 | 2 | 0 | 2 | 1 | 1 | 1 |
| Any AEs, Grade 5 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 1 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-related events were those assessed by the investigator as related to study medication. CTCAE version 3.0 was used for AE grading: Grade 1 mild AE; Grade 2 moderate AE; Grade 3 severe AE; Grade 4 life-threatening or disabling AE; Grade 5 death related to AE.
| participants | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|---|
| Any AEs, Grade 1 | 1 | 0 | 1 | 1 | 1 | 6 | 2 | 0 | 3 |
| Any AEs, Grade 2 | 1 | 1 | 0 | 3 | 2 | 6 | 4 | 1 | 0 |
| Any AEs, Grade 3 | 0 | 0 | 1 | 1 | 1 | 8 | 10 | 2 | 1 |
| Any AEs, Grade 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Any AEs, Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Missing or Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Criteria for potentially important changes in ECG were defined as: maximum (max.) post-dose (post-baseline) time from electrocardiogram Q wave to the corresponding to electrical systole (QT interval) corrected for Fridericia's factor (QTcF), or QT interval corrected for Bazett's factor (QTcB): \<450, 450 -\<480, 480-\<500, and \>=500 msec. Maximum increase (inc.) from baseline in QTcF or QTcB: change (chg) \<30, 30\>=chg\<60, and chg \>=60 msec.
| participants | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|---|
| Max. QTcB interval <450 msec | 0 | 3 | 2 | 4 | 2 | 11 | 5 | 2 | 8 |
| Max. QTcB interval 450-<480 msec | 3 | 0 | 1 | 3 | 2 | 8 | 9 | 1 | 8 |
| Max. QTcB interval 480-<500 msec | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 0 | 8 |
| Max. QTcB interval >=500 msec | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 8 |
| Max. QTcF interval <450 msec | 3 | 3 | 2 | 7 | 3 | 13 | 12 | 3 | 8 |
| Max. QTcF interval 450-<480 msec | 0 | 0 | 1 | 0 | 1 | 9 | 2 | 0 | 0 |
| Max. QTcF interval 480-<500 msec | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Max. QTcF interval >=500 msec | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Max. QTcB interval inc. from baseline chg<30 msec | 1 | 2 | 1 | 7 | 3 | 21 | 7 | 3 | 7 |
| Max. QTcB interval inc. from baseline 30=<chg<60 | 2 | 1 | 2 | 1 | 1 | 2 | 7 | 0 | 1 |
| Max. QTcB interval inc. from baseline chg>=60 msec | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Max. QTcF interval inc. from baseline chg<30 msec | 3 | 2 | 1 | 7 | 3 | 22 | 12 | 3 | 8 |
| Max. QTcF interval inc. from baseline 30=<chg<60 | 0 | 1 | 2 | 1 | 1 | 1 | 2 | 0 | 0 |
| Max. QTcF interval inc. from baseline chg>=60 msec | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
Parameters analyzed included: white blood cell (WBC) count plus differential, absolute (abs) neutrophil count, platelets, hemoglobin, sodium, potassium, bicarbonate, chloride, blood urea nitrogen, creatinine, glucose, uric acid, calcium, phosphate, magnesium, total protein, albumin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), partial prothrombin time/international normalized ratio (PTT/INR). Urinalysis: pH, specific gravity, protein, glucose, ketones, blood, leukocyte esterase, and nitrites. Pregnancy test: Serum or urine pregnancy test for women of childbearing potential. There were no changes in urine protein among the solid tumor and T-ALL/LBL participants that were clinically significant. Clinical significance was judged by the investigator.
| participants | PF-03084014 in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|
| Hemoglobin | 45 | 8 |
| Lymphocytes (abs) | 40 | 8 |
| Neutrophils (abs) | 4 | 5 |
| Platelets | 13 | 6 |
| WBC | 4 | 5 |
| ALT | 22 | 4 |
| ALP | 24 | 3 |
| AST | 32 | 4 |
| Bicarbonate | 15 | 1 |
| Bilirubin | 10 | 2 |
| Creatinine | 17 | 1 |
| Hypercalcaemia | 17 | 0 |
| Hyperglycaemia | 55 | 6 |
| Hyperkalaemia | 4 | 0 |
| Hypermagnesaemia | 1 | 0 |
| Hypernatraemia | 4 | 0 |
| Hypoalbuminaemia | 43 | 6 |
| Hypocalcaemia | 18 | 6 |
| Hypoglycaemia | 6 | 0 |
| Hypokalaemia | 23 | 4 |
| Hypomagnesaemia | 8 | 1 |
| Hyponatraemia | 19 | 3 |
| Hypophosphataemia | 54 | 4 |
Cmax was the maximum observed serum concentration.
| nanogram/milliliter (ng/mL) | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) After a Single Dose on Cycle 1 Day 1 | 163 ± 62 | 368 ± 48 | 230 ± 193 | 691 ± 37 | 536 ± 72 | 943 ± 100 | 861 ± 63 | 1892 ± 54 | 1604 ± 85 |
Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.
| ng/mL/mg | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|---|
| Dose-normalized Cmax [Cmax (dn)] After a Single Dose on Cycle 1 Day 1 | 8.1 ± 63 | 9.2 ± 48 | 2.9 ± 193 | 6.9 ± 37 | 4.1 ± 72 | 6.3 ± 100 | 3.9 ± 63 | 5.7 ± 54 | 10.7 ± 85 |
AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). CV is the coefficient of variation.
| nanogram*hour/milliliter (ng*hr/mL) | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Time-Concentration Curve From Time 0 to the Dosing Interval (AUCtau) After a Single Dose on Cycle 1 Day 1 | 409 ± 83 | 1329 ± 87 | 1649 ± 98 | 2204 ± 37 | 2924 ± 81 | 3677 ± 86 | 3593 ± 58 | 8014 ± NA | 6412 ± 80 |
AUCtau (dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. NE is not estimable.
| ng*hr/mL/mg | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|---|
| Dose-normalized AUCtau [AUCtau (dn) ] After a Single Dose on Cycle 1 Day 1 | 20.4 ± 83 | 33.2 ± 87 | 20.6 ± 98 | 22.0 ± 37 | 22.5 ± 81 | 24.5 ± 86 | 16.3 ± 58 | 24.3 ± NA | 42.7 ± 80 |
Tmax was the time to reach maximum serum concentration (Cmax).
| hours | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|---|
| Time to Reach Cmax (Tmax) After a Single Dose on Cycle 1 Day 1 | 1.0 (0.9 to 1.0) | 1.0 (1.0 to 1.3) | 2.0 (1.0 to 8.0) | 1.0 (1.0 to 2.0) | 2.5 (1.0 to 4.0) | 1.1 (0.5 to 4.1) | 2.0 (1.0 to 4.1) | 1.2 (1.0 to 2.0) | 1.1 (0.9 to 4.0) |
Cmax was the maximum observed serum concentration. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant. CV is the coefficient of variation.
| ng/mL | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|
| Cmax After Multiple Dose on Cycle 1 Day 21 | 64.5 ± NA | 381 ± NA | 313 ± 29 | 867 ± 44 | 421 ± 130 | 1246 ± 79 | 1864 ± 76 | 1828 ± 42 |
Tmax was the time to reach maximum serum concentration (Cmax). Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
| hour | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|
| Time to Reach Cmax (Tmax) After Multiple Dose on Cycle 1 Day 21 | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) | 1.1 (1.0 to 4.0) | 1.0 (1.0 to 2.7) | 3.7 (1.0 to 8.0) | 1.1 (1.0 to 4.0) | 1.0 (0.5 to 2.0) | 1.6 (1.0 to 2.0) |
AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
| ng*hr/mL | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|
| AUCtau After Multiple Dose on Cycle 1 Day 21 | 309.0 ± NA | 2521 ± NA | 1572 ± 42 | 4741 ± 70 | 3155 ± 59 | 6430 ± 89 | 10520 ± 89 | 9161 ± 30 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired concentration of a drug. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
| liter (L) | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) on Cycle 1 Day 21 | 2810 ± NA | 516 ± NA | 3353 ± NA | 986 ± 52 | 2048 ± 49 | 801 ± 144 | 852 ± 120 | 424 ± 61 |
Serum decay half-life (t1/2) is the time measured for the serum concentration to decrease by one half. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
| hours | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|
| Serum Decay Half-Life (t1/2) After Multiple Dose on Cycle 1 Day 21 | 30.3 ± NA | 22.6 ± NA | 38.6 ± NA | 34.2 ± 11.7 | 34.7 ± 5.3 | 25.3 ± 9.2 | 29.3 ± 9.3 | 18.0 ± 3.6 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
| liter/hour (L/hr) | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|
| Apparent Oral Clearance (CL/F) on Cycle 1 Day 21 | 64.8 ± NA | 15.9 ± NA | 50.9 ± 42 | 21.1 ± 70 | 41.2 ± 59 | 23.4 ± 88 | 20.9 ± 89 | 16.4 ± 30 |
Cmin was the minimum serum concentration. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
| ng/mL | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|
| Minimum Observed Serum Concentration (Cmin) After Multiple Dose on Cycle 1 Day 21 | 10.7 ± NA | 126 ± NA | 59.2 ± 103 | 232 ± 118 | 206 ± 40 | 266 ± 102 | 469 ± 118 | 420 ± 81 |
Cavg was the average serum concentration at steady state. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
| ng/mL | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|
| Average Serum Concentration (Cavg) at Steady State on Cycle 1 Day 21 | 25.7 ± NA | 210 ± NA | 131 ± 42 | 395 ± 69 | 263 ± 59 | 536 ± 89 | 877 ± 89 | 763 ± 30 |
Accumulation was calculated as AUCtau at steady state (Cycle 1 Day 21) divided by AUCtau after a single dose on Cycle 1 Day 1. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
| ratio | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|
| Accumulation Ratio (Rac) on Cycle 1 Day 21 | 1.18 (0.72 to 1.63) | 1.60 (1.45 to 1.74) | 1.36 (0.93 to 1.79) | 2.49 (1.23 to 2.86) | 1.98 (1.81 to 2.15) | 2.29 (0.95 to 4.90) | 2.84 (1.14 to 5.80) | 0.97 (NA to NA) |
AUCtau (dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
| ng*hr/mL/mg | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|
| Dose-normalized AUCtau [AUCtau (dn)] After Multiple Dose on Cycle 1 Day 21 | 15.4 ± NA | 63.0 ± NA | 19.7 ± 41 | 47.4 ± 70 | 24.3 ± 59 | 42.9 ± 88 | 47.9 ± 89 | 61.1 ± 30 |
Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.
| ng/mL/mg | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|---|---|---|---|---|---|---|
| Dose-normalized Cmax [Cmax (dn)] After Multiple Dose on Cycle 1 Day 21 | 3.2 ± NA | 9.6 ± NA | 3.9 ± 29 | 8.7 ± 44 | 3.2 ± 130 | 8.3 ± 79 | 8.5 ± 76 | 12.2 ± 42 |
AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval).
| ng*hr/mL | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants |
|---|---|---|
| AUCtau in the Fasted State for Solid Tumor Participants | 2547 ± 101 | 9353 ± 100 |
AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval).
| ng*hr/mL | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants |
|---|---|---|
| AUCtau in the Fed State for Solid Tumor Participants | 3163 ± 83 | 5573 ± 39 |
Cmax was the maximum observed serum concentration.
| ng/mL | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants |
|---|---|---|
| Cmax in the Fasted State for Solid Tumor Participants | 795.1 ± 104 | 2334 ± 93 |
Cmax was the maximum observed serum concentration.
| ng/mL | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants |
|---|---|---|
| Cmax in the Fed State for Solid Tumor Participants | 862.3 ± 74 | 924.4 ± 40 |
AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose.
| ng*hr/mL/mg | PF-03084014 in Solid Tumor Participants |
|---|---|
| Dose-normalized AUCtau [AUCtau(dn)] in the Fasted State for Solid Tumor Participants | 23.71 ± 115 |
AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose.
| ng*hr/mL/mg | PF-03084014 in Solid Tumor Participants |
|---|---|
| Dose-normalized AUCtau [AUCtau(dn)] in the Fed State for Solid Tumor Participants | 22.54 ± 67 |
Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.
| ng/mL/mg | PF-03084014 in Solid Tumor Participants |
|---|---|
| Dose-normalized Cmax [Cmax(dn)] in the Fasted State for Solid Tumor Participants | 6.56 ± 106 |
Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.
| ng/mL/mg | PF-03084014 in Solid Tumor Participants |
|---|---|
| Dose-Normalized Cmax [Cmax(dn)] in the Fed State for Solid Tumor Participants | 5.22 ± 64 |
AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). Data for this outcome measure was planned to be analyzed for two arms only.
| ng*hr/mL | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants |
|---|---|---|
| AUCtau on Cycle 2 Day 1 | 2784 ± 80 | 11870 ± 57 |
AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. Data for this outcome measure was planned to be analyzed for two arms only.
| ng*hr/mL/mg | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants |
|---|---|---|
| Dose-normalized AUCtau [AUCtau (dn)] on Cycle 2 Day 1 | 18.6 ± 80 | 54.0 ± 57 |
Cmax was the maximum observed serum concentration. Data for this outcome measure was planned to be analyzed for two arms only.
| ng/mL | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants |
|---|---|---|
| Cmax on Cycle 2 Day 1 | 834.6 ± 76 | 2640 ± 63 |
Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose. Data for this outcome measure was planned to be analyzed for two arms only.
| ng/mL/mg | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants |
|---|---|---|
| Dose-normalized Cmax [Cmax (dn)] on Cycle 2 Day 1 | 5.6 ± 76 | 12.0 ± 63 |
Tmax was the time to reach maximum serum concentration (Cmax). Data for this outcome measure was planned to be analyzed for two arms only.
| hr | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants |
|---|---|---|
| Tmax on Cycle 2 Day 1 | 2.00 (1.00 to 4.03) | 1.53 (0.98 to 4.00) |
Objective response (OR) was defined as confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as \>=30% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study \>=4 weeks after initial documentation of response.
| percentage of participants | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants |
|---|---|---|---|---|---|---|---|---|
| Percentage of Solid Tumor Participants With Objective Response (OR) | 33.3 (0.8 to 90.6) | 0 (0.0 to 70.8) | 66.7 (9.4 to 99.2) | 0 (0.0 to 52.2) | 0 (0.0 to 70.8) | 5.6 (0.1 to 27.3) | 10.0 (0.3 to 44.5) | 100 (2.5 to 100.0) |
Time from Cycle 1 Day 1 to first documentation of disease progression. Progression was defined as per RECIST version 1.0, as a 20% increase in the sum of the longest diameter of target lesions, or target lesions over nadir, uneuivocal progression of non-target disease, or the appearance of new lesions. TTP (months) was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.
| months | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants |
|---|---|---|---|---|---|---|---|---|
| Time to Tumor Progression (TTP) for Solid Tumor Participants | NA (0.8 to NA) | 1.2 (1.0 to 2.8) | NA (1.7 to NA) | 3.1 (1.0 to NA) | 4.3 (1.6 to 19.5) | 1.6 (1.4 to 6.0) | 1.5 (1.1 to 4.2) | NA (NA to NA) |
Time from the first documentation of OR to objective disease progression or death due to any cause. DR was only calculated for participants with an OR. DR (months) was calculated as (date of first documentation of objective progression or death minus date of first documentation of PR or CR plus 1) divided by 30.
| months | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants |
|---|---|---|---|---|---|
| Duration of Response (DR) for Solid Tumor Participants | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
PFS was defined as the time from Cycle 1 Day 1 to date of first documentation of progression or death due to any cause. Progression was defined as per RECIST version 1.0, as a 20% increase in the sum of the longest diameter of target lesions, or target lesions over nadir, unequivocal progression of non-target disease, or the appearance of new lesions. PFS (months) was calculated as (the first event date minus the date of first dose of study medication plus 1) divided by 30.
| months | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants |
|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) for Solid Tumor Participants | NA (0.8 to NA) | 1.2 (1.0 to 2.8) | NA (1.7 to NA) | 2.3 (0.4 to NA) | 4.3 (1.6 to 19.5) | 1.6 (1.4 to 6.0) | 1.5 (1.1 to 4.2) | NA (NA to NA) |
OR was adapted from International Working Group Response Criteria for Acute Myeloid Leukemia (AML). The response categories of interest were CR, complete response with incomplete hematopoietic recovery (CRi), and PR. CR: ANC \>1500/microliter (uL), no circulating blasts. Platelets \>100,000/uL, \<5% marrow blast cells, no extramedullary disease, bone marrow cellularity \>20% with tri-lineage hematopoiesis and \<5% marrow blast cells, none of which were neoplastic; CRi: same as CR but ANC may be \>1500/uL or platelet count \>100,000/uL, no requirement on bone marrow cellularity; PR: same as CR but bone marrow with \>= 50% reduction of leukemia blast cells and an absolute blast count between 5% and 25%.
| percentage of participants | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|
| Percentage of T-ALL/LBL Participants With OR | 12.5 (0.3 to 52.7) |
The RFS of CR was defined as the time from the date of first attaining CR to the date of relapse or death from any cause, whichever occurred first. Similarly, the RFS of CR + CRi (or RFS of CR + CRi + PR) was defined as the time from the date of first attaining CR + CRi (or CR + CRi + PR) to the date of relapse or death from any cause, whichever occurred first.
No measurements were reported for this outcome.
PBR was the maximum percentage of peripheral blast count reduction for each participant who received at least one dose of study medication. PBR was derived by the Sponsor from percentage of peripheral blood Blast Count reported by sites.
No measurements were reported for this outcome.
Gene expression analysis in tumor biopsies was done using cDNA prepared from RNA extracted from tumor biopsies. Gene expression was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Only Hes4 gene showed consistent down modulation across dosing cohorts (150 mg and 220 mg BID) and therefore results were reported for Hes4 only. Data for this outcome measure was planned to be analyzed for two arms only.
| ratio | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants |
|---|---|---|
| Changes in Expression Levels of Notch 1 Target Genes in Tumor Biopsies for Solid Tumor Participants: Hairy and Enhancer of Split-4 (Hes4) Gene Expression Levels on Cycle 1 Day 21 Relative to That at Baseline | 0.9 ± 0.57 | 0.5 ± 0.50 |
Ribonucleic acid (RNA) was extracted from peripheral blood and used as a template to synthesize complementary deoxyribonucleic acid (cDNA). Gene expression in cDNA was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Results were reported Only for Hes4 as this was the only gene to show consistent down modulation across dosing cohorts (150 mg and 220 mg).
| ratio | PF-03084014 150 mg BID in T-ALL/LBL Participants |
|---|---|
| Cycle 1 Day 8 | 0.7 ± 0.65 |
| Cycle 1 Day 15 | 0.3 ± 0.41 |
| Cycle 1 Day 21 | 0.4 ± 0.27 |
| EOT | 2.0 ± NA |
Ribonucleic acid (RNA) was extracted from peripheral blood and used as a template to synthesize complementary deoxyribonucleic acid (cDNA). Gene expression in cDNA was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Results were reported Only for Hes4 as this was the only gene to show consistent down modulation across dosing cohorts (150 mg and 220 mg).
| ratio | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants |
|---|---|---|
| Cycle 1 Day 8 | 0.3 ± 0.24 | 0.1 ± 0.14 |
| Cycle 1 Day 21 | 0.3 ± 0.33 | 0.0 ± 0.02 |
Notch intracellular domain (NICD) levels was measured in peripheral blood mononuclear cell (PBMC) pellets using a validated enzyme-linked immunosorbent assay (ELISA).
No measurements were reported for this outcome.
Notch intracellular domain (NICD) was to be measured in bone marrow monoculear cell (BMMC) cell pellets using a validated ELISA.
No measurements were reported for this outcome.
Time to response (TTR) was only defined for participants with an objective response (OR). TTR (months) was calculated as (date of first documentation of PR or CR minus date of first dose of study medication plus 1) divided by 30.
| months | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants |
|---|---|---|---|---|---|
| Time to Response (TTR) for Solid Tumor Participants | 11.2 (NA to NA) | 19.4 (8.5 to 30.4) | 2.9 (NA to NA) | 10.1 (NA to NA) | 5.9 (NA to NA) |
Collected over Baseline up to end of study (maximum of 84 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-03084014 20 mg BID in Solid Tumor Participants | — | 1/3 (33.3%) | 3/3 (100%) |
| PF-03084014 40 mg BID in Solid Tumor Participants | — | 1/3 (33.3%) | 3/3 (100%) |
| PF-03084014 80 mg BID in Solid Tumor Participants | — | 2/4 (50%) | 4/4 (100%) |
| PF-03084014 100 mg BID in Solid Tumor Participants | — | 4/8 (50%) | 7/8 (87.5%) |
| PF-03084014 130 mg BID in Solid Tumor Participants | — | 2/4 (50%) | 3/4 (75%) |
| PF-03084014 150 mg BID in Solid Tumor Participants | — | 8/23 (34.8%) | 23/23 (100%) |
| PF-03084014 150 mg BID in T-ALL/LBL Participants | — | 4/8 (50%) | 8/8 (100%) |
| PF-03084014 220 mg BID in Solid Tumor Participants | — | 7/16 (43.8%) | 16/16 (100%) |
| PF-03084014 330 mg BID in Solid Tumor Participants | — | 2/3 (66.7%) | 3/3 (100%) |
| Event | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants |
|---|---|---|---|---|---|---|---|---|---|
| GRAM POSITIVE COCCIInvestigations | 0/3 | 0/3 | 0/4 | 0/8 | 0/4 | 0/23 | 0/8 | 0/16 | 1/2 |
| NauseaGastrointestinal disorders | 0/3 | 0/3 | 0/4 | 0/8 | 2/4 | 0/8 | 0/8 | 0/16 | 0/2 |
| SepsisInfections and infestations | 0/3 | 0/3 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/16 | 1/2 |
| HypophosphataemiaMetabolism and nutrition disorders | 0/3 | 0/3 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/16 | 1/2 |
| ConstipationGastrointestinal disorders | 1/3 | 0/3 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/16 | 0/2 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 0/3 | 0/4 | 0/8 | 1/4 | 0/8 | 0/8 | 0/16 | 0/2 |
| Disease progressionGeneral disorders | 0/3 | 1/3 | 0/4 | 1/8 | 0/4 | 0/8 | 1/8 | 2/16 | 0/2 |
| VomitingGastrointestinal disorders | 0/3 | 0/3 | 0/4 | 0/8 | 1/4 | 0/8 | 0/8 | 0/16 | 0/2 |
| MalaiseGeneral disorders | 0/3 | 0/3 | 0/4 | 0/8 | 1/4 | 0/8 | 0/8 | 0/16 | 0/2 |
| Joint dislocationInjury, poisoning and procedural complications | 0/3 | 0/3 | 1/4 | 0/8 | 0/4 | 0/8 | 0/8 | 1/16 | 0/2 |
| Event | PF-03084014 20 mg BID in Solid Tumor Participants | PF-03084014 40 mg BID in Solid Tumor Participants | PF-03084014 80 mg BID in Solid Tumor Participants | PF-03084014 100 mg BID in Solid Tumor Participants | PF-03084014 130 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in Solid Tumor Participants | PF-03084014 150 mg BID in T-ALL/LBL Participants | PF-03084014 220 mg BID in Solid Tumor Participants | PF-03084014 330 mg BID in Solid Tumor Participants |
|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/3 | 0/3 | 2/4 | 0/8 | 3/4 | 2/8 | 2/8 | 12/16 | 3/3 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 2/3 | 0/4 | 1/8 | 1/4 | 7/8 | 0/8 | 3/16 | 1/3 |
| NauseaGastrointestinal disorders | 2/3 | 0/3 | 1/4 | 2/8 | 3/4 | 5/8 | 5/8 | 8/16 | 2/3 |
| HypophosphataemiaMetabolism and nutrition disorders | 0/3 | 0/3 | 2/4 | 2/8 | 2/4 | 6/8 | 0/8 | 9/16 | 1/3 |
| FlatulenceGastrointestinal disorders | 2/3 | 1/3 | 0/4 | 0/8 | 0/4 | 1/8 | 0/8 | 0/16 | 0/3 |
| VomitingGastrointestinal disorders | 0/3 | 0/3 | 1/4 | 2/8 | 2/4 | 5/8 | 5/8 | 5/16 | 2/3 |
| FatigueGeneral disorders | 2/3 | 2/3 | 2/4 | 1/8 | 1/4 | 7/16 | 0/8 | 7/16 | 1/3 |
| Mucosal inflammationGeneral disorders | 1/3 | 0/3 | 1/4 | 0/8 | 0/4 | 2/8 | 0/8 | 0/16 | 2/3 |
| HeadacheNervous system disorders | 2/3 | 0/3 | 0/4 | 0/8 | 0/4 | 2/8 | 1/8 | 3/16 | 1/3 |
| RashSkin and subcutaneous tissue disorders | 2/3 | 1/3 | 0/4 | 1/8 | 0/4 | 4/8 | 0/8 | 3/16 | 2/3 |
| Age, Continuous(years) | PF-03084014 in Solid Tumor Participants | PF-03084014 in T-ALL/LBL Participants | Total |
|---|---|---|---|
| Mean | 55.6 ± 14.7 | 30.8 ± 9 | 52.9 ± 16.1 |
| Sex: Female, Male(Participants) | PF-03084014 in Solid Tumor Participants | PF-03084014 in T-ALL/LBL Participants | Total |
|---|---|---|---|
| Female | 33 | 2 | 35 |
| Male | 31 | 6 | 37 |
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jun 2009 to primary completion in Jan 2013, 42 months.
Results were first posted in Nov 2019, 6 years 10 months after primary completion.
Of 51 industry-sponsored phase 1 interventional studies under Leukemia, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 42 months is close to that.
Counting every sponsor, half of 164 studies reached it within 53 months; a quarter within 34 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirogacestat